Literature DB >> 10455339

Cyclophosphamide metabolism in children with Fanconi's anaemia.

S M Yule1, L Price, M Cole, A D Pearson, A V Boddy.   

Abstract

Although patients with Fanconi's anaemia (FA) exhibit a heightened sensitivity to DNA cross-linking agents, modified doses of CY continue to be used in their conditioning prior to BMT. We measured the pharmacokinetics and metabolism of CY in six children with FA using an established high performance thin layer chromatography technique. CY doses ranged between 5 and 20 mg/kg (median 10 mg/kg). The median CY clearance was 0.6 l/h/m2 (range 0.4-1.1 l/h/m2), t1/2 was 8.1 h (range 6.7-9.5 h) and volume of distribution was 0.19 l/kg (range 0.16-0.34 l/kg), respectively. These results contrast with those previously reported from a comparable group of non-FA children in whom the median CY clearance was 3.2 l/h/m2 (range 2-5 l/h/m2) (P = 0.035), t1/2 was 2.4 h (range 2-3.8 h) (P = 0.035) and volume of distribution 0.5 l/kg (range 0.26-0.95 l/kg) (NS). Unlike the control group in whom the presence of inactive metabolites of CY was common, metabolites could not be found in any FA patient. The enhanced sensitivity of children with FA to CY may in part result from altered drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455339     DOI: 10.1038/sj.bmt.1701868

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Formation of cyclophosphamide specific DNA adducts in hematological diseases.

Authors:  L'Aurelle A Johnson; Bhaskar Malayappan; Natalia Tretyakova; Colin Campbell; Margaret L MacMillan; John E Wagner; Pamala A Jacobson
Journal:  Pediatr Blood Cancer       Date:  2011-07-25       Impact factor: 3.167

3.  Successful treatment of fanconi anemia and T-cell acute lymphoblastic leukemia.

Authors:  Terrie Flatt; Kathleen Neville; Karen Lewing; Jignesh Dalal
Journal:  Case Rep Hematol       Date:  2012-04-01

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.